Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

CRBU

C

Caribou Biosciences, Inc. (CRBU)

NMS – Цена в реальном времени. Валюта: USD

2.03

0.00 (0.00%)

Рынок открыт: May 13, 2026, 9:32 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology Association (EHA) Annual Meeting, which will be held June 11-14, 2026, in Stockholm, Sweden.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.43 per share a year ago.

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMouflage phase 1 trial evaluating CB-011 continues to enroll r/r MM patients, dose escalation and expansion clinical data updates expected in 2026 -- BERKELEY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter of 2026 and provided a business update.

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at BofA Securities 2026 Health Care Conference on May 13, 2026, at 8:40am PT in Las Vegas, Nevada.

Three Best Genomics Stocks for Your Portfolio in 2026

Three Best Genomics Stocks for Your Portfolio in 2026

Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient cohort -- -- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 -- BERKELEY, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for relapsed or refractory multiple myeloma (r/r MM).

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.

Видео

No Data

There is no data to display

Пресс-релизы

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology Association (EHA) Annual Meeting, which will be held June 11-14, 2026, in Stockholm, Sweden.

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMouflage phase 1 trial evaluating CB-011 continues to enroll r/r MM patients, dose escalation and expansion clinical data updates expected in 2026 -- BERKELEY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter of 2026 and provided a business update.

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at BofA Securities 2026 Health Care Conference on May 13, 2026, at 8:40am PT in Las Vegas, Nevada.

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient cohort -- -- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 -- BERKELEY, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for relapsed or refractory multiple myeloma (r/r MM).